Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alizé Pharma II
Lyon, France
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead program, pegcrisantaspase (Asparec), reached Phase 2/3 clinical trials for patients with acute lymphoblastic leukemia (ALL) who have hypersensitivity to E. coli-derived L-asparaginase. It showed preclinical evidence of being longer-acting and less immunogenic than earlier Erwinia-derived products. The drug received Fast Track and Orphan Drug designations in the US and EU[2][1].
- Therapeutic areas
- Oncology
- Modalities
- Recombinant proteinPEGylated enzymeBiologic
- Industry
- Biotech
02
Partnerships
EUSA Pharma (licensed lead asset before EUSA was acquired by Jazz Pharmaceuticals)
Beyond the preview
Go deeper on Alizé Pharma II.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alizé Pharma II.